Policy on Communication with Shareholders and Investors

Our Investors Relationship (IR) information disclosure policy requires the timely, proactive, and continuous disclosure of information that is both transparent and impartial in compliance with rules governing disclosure. Although information such as the value of our pipeline (the new products under development) is difficult to quantify, we strive to facilitate shareholders’ and investors’ understanding by proactively disclosing IR information.
With the aim of achieving interactive communication, we are working to increase opportunities to provide IR information and enhance its content while grasping the needs of our shareholders and investors through interviews and questionnaires, rather than by providing information unilaterally.
For example, in response to the need to secure sufficient time to exercise voting rights, we post a convocation notice of the general meetings of shareholders on our website as early as possible. Furthermore, in response to the requests of shareholders who find it difficult to participate from distant locations, we offer live streaming of the meetings. Deepening mutual understanding with our shareholders and investors through a sound exchange of views is essential for improving our corporate value. Going forward, we will strive to communicate proactively according to our IR activity policy.

Proactive IR Activities

We presented quarterly financial results and conducted R&D Day (R&D briefing). Furthermore, we also held briefing sessions (including briefing sessions based on requests from securities companies) focusing on key highlights of the data for our pipeline projects presented at major medical congresses for institutional investors immediately after the presentations. In FY2023, we set up approximately 250 opportunities for dialogue with institutional investors in Japan and outside Japan through participation in conferences sponsored by securities companies, individual meetings, etc. in addition to regular IR coverage.
We enhance communication beyond location constraints by utilizing virtual technologies. In FY2023, we live-streamed the general meeting of shareholders, in addition to the virtual briefing sessions for our shareholders and individual investors by Representative Director, President and CFO, which were well received by the shareholders and investors who previously were unable to participate in the event.

Sustainability Dialogue with Investors

We have increasingly engaged in dialogue with institutional investors on sustainability-related topics such as governance, access to healthcare, and environmental initiatives in addition to financial information so far. To foster more constructive dialogue, we are committed to providing transparent and meaningful non-financial information to our investors.

In November 2025, we held the 5th Sustainability Meeting (formerly the ESG Briefing) for institutional investors and securities analysts. The meeting aimed to deepen participants’ understanding of our management approach, drawing on the Value Report 2025 published in September 2025, and to incorporate investor feedback into our future initiatives, thereby contributing to sustainable value creation.

The hybrid event attracted approximately 70 participants, both in person and online, and featured active and engaging discussions. Our internal and outside directors, together with our CEO, took the stage to discuss our approach to sustainability management and human capital, with a particular focus on two key areas—Patient Centricity and Governance. Our CEO and directors provided detailed explanations of our concrete activities in these areas and received valuable insights and feedback from investors. 

Dissemination of Other Information

We provide an “Investors” page on our corporate website, which aggregates financial results, other presentation materials (“IR Library”), information on the general meeting of shareholders (“Shareholders/Stock Information”), and major financial information (“Financial Highlights”), etc. Among these contents, the “For Individual Investors” page provides general information on the pharmaceutical industry and market, as well as the Company’s characteristics and management strategy, etc. in an easy-to-understand format for individual investors who are new to our information. In addition, we issue bimonthly IR e-mail magazines to investors in Japan, featuring recent topics related to the Group.
Furthermore, through our integrated report, the Value Report, we provide our management’s views, and the history, strengths, and growth potential of our company, along with other non-financial information to our shareholders and investors to facilitate understanding of  sustainable growth of our corporate values.
Going forward, we will continue to disseminate financial and non-financial information that meets the expectations of our stakeholders.

Increased Importance of CSR and ESG Information Disclosure

Companies operating globally are significantly affected by changes in the natural environment, economic trends, technological innovation, and the social system of each country or region. Such changes include internet of things (IoT), artificial intelligence (AI), and other digital technologies and biotechnologies, as well as economic and geopolitical changes, drastic changes in demographics, such as decreasing birthrate and aging population in developed countries and increasing population in emerging countries, as well as changes in the global environment. We recognize it is important to disclose both financial information and sustainability and environmental, social, and governance (ESG) information in the same way for our stakeholders to understand the opportunities and risks that are associated with such changes the company is facing.
Following the guidelines on sustainability reporting in Europe, many other countries and regions require disclosure on initiatives for the environment pertaining to the impact on climate change, for society pertaining to human rights and diversity initiatives, and for governance pertaining to anti-corruption and bribery prevention efforts. Since the reliability of numerical information on such initiatives is also required, the importance of ensuring reliability is also increasing. As ESG disclosures may be used for investment decision-making, the reliability of such information disclosed by a company should be reviewed by an independent third party. This is becoming an important criteria in ESG management.

Daiichi Sankyo Group of Companies Initiatives

As the Company Corporate Conduct Charter declares “fair disclosure of information and constructive dialogue with stakeholders” in Article 3, we also promote proactive, effective, and fair disclosure of sustainability and ESG information. We have been receiving third party assurance for our major social data since FY2018 and major environmental data since FY2019, respectively, with regards to data collection, calculation, and disclosure. The Daiichi Sankyo Group will continue to strive to ensure its reliability and improve the quality and quantity of data disclosed.

ESG Data